Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

One hundred endometrium specimens have been studied with flow cytometry for DNA analysis (FCDA) and a proliferative enzyme marker, 5'-nucleotide phosphodiesterase (5'-NPD). FCDA data showed that aneuploidy was present in only 5 of 40 cancer specimens. However, with corrected histograms, a higher DNA value was observed in the G2/M (6%) of all cancer compared with noncancer specimens (4%). Thus, FCDA can be a useful diagnostic aid for endometrial cancer. The determination of 5'-NPD was done with a quenching method based on the use of 5'-(5-iodo-3-indoxyl)-thymidine phosphodiester as a substrate and 4',6-diamidino-2-phenylindole for DNA. This method could qualitatively define which population of the cell cycle had a higher enzyme level and also quantitatively gave the enzyme units per cell. It was found that 12.5% of all cancer specimens had 5'-NPD activity in the G0/G1 cells and 87.5% in the S and/or G2/M cells, whereas in the noncancer specimens 5'-NPD was found in 28.5% of the G0/G1 cells and 71.5% of the specimens had 5'-NPD in the S and/or G2/M cells. Furthermore, the concentration of 5'-NPD was found to be five times higher in the G2/M cells of the cancer specimens than that in the noncancer specimens. However, in the hyperplasia specimens, the activity was only two times higher in the same cell cycle fraction than in the normal specimens. The results of this investigation provided for the first time evidence that this exonuclease activity alters in the cell cycle fractions and that a decrease in the enzyme activity in G0/G1 cells and an increase in G2/M cells may be a useful marker for neoplastic development in human endometrial cancer.
 ...
PMID:Flow cytometric DNA and 5'-nucleotide phosphodiesterase in endometrium. 299 53

It has been reported that various types of immunoactivators can induce Graves' disease. We describe here a case of Graves' disease during treatment with sizofiran, an immunoactivator. A 42-year-old woman who had previously been in an euthyroid state with Hashimoto's thyroiditis, experienced thyrotoxicosis during continuous administration of sizofiran as immunotherapy for endometrial carcinoma. Since the TSH receptor-antibody was positive, and a thyroid scintigram showed diffuse goiter and high uptake, she was diagnosed as having Graves' disease. It is suggested that the administration of sizofiran may be one of the triggers of Graves' disease.
 ...
PMID:Graves' disease development during sizofiran treatment. 1248 71

Upper gastrointestinal metastasis of endometrial carcinoma rarely occurs in the absence of locoregional disease and other distant metastases. We describe herein the unique case of an isolated gastric metastasis of a stage I endometrial adenocarcinoma. Because the metastatic tumor was initially misdiagnosed clinically and pathologically as a primary gastric carcinoma, we illustrate the histopathology and review the pertinent literature. A 42-year-old woman with Lynch syndrome underwent treatment of endometrial adenocarcinoma at an outside hospital comprising clinical and radiological staging including a positron emission tomography-computed tomography (PET-CT) scan followed by a total intra-abdominal hysterectomy, bilateral salpingoophorectomy and pelvic and paraaortic lymphadenectomy. The preoperative and pathology findings were consistent with a stage I tumor. Three months postoperatively, a PET-CT scan revealed a new 4.4 cm hypermetabolic lesion in the stomach. A biopsy of the lesion was interpreted pathologically as gastric adenocarcinoma with lymphoid stroma. Upon referral of the patient to our center for management, the biopsy was reviewed in consultation and the pathology materials from the hysterectomy procedure were retrieved for comparison. Based on the morphological and immunohistochemical similarities between the tumors the gastric tumor was diagnosed as metastatic endometrial adenocarcinoma. To our knowledge, this is the first documented case of an isolated gastric metastasis complicating stage I endometrial adenocarcinoma. Awareness of the potential for this occurrence and of the associated diagnostic pitfalls is crucial for accurate diagnosis and therapy.
 ...
PMID:Isolated Gastric Metastasis of Endometrial Adenocarcinoma: First Case Report and Review of Pertinent Literature. 3062 66